Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRCA2 oncogenic variants status confers therapeutic sensitivity to Olaparib in patients with Ovarian Epithelial Tumor.
The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
This statement is based on a regulatory approval from the Health Service Executive:
Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy